XAIR
Beyond Air Inc (XAIR)
Healthcare • NASDAQ • $4.91-2.58%
- Symbol
- XAIR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $4.91
- Daily Change
- -2.58%
- Market Cap
- $4.96M
- Trailing P/E
- 0.02
- Forward P/E
- -3.04
- 52W High
- $95.60
- 52W Low
- $4.88
- Analyst Target
- $30.00
- Dividend Yield
- N/A
- Beta
- 0.15
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Developmen…
Company websiteResearch XAIR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.